<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258282</url>
  </required_header>
  <id_info>
    <org_study_id>YSP20140688</org_study_id>
    <nct_id>NCT02258282</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Etanercept in Patients With Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy of etanercept in patients with
      psoriasis who had an unsatisfactory response to traditional DMARDs.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of Physician's Global Assessment (PGA) at 24 weeks</measure>
    <time_frame>At 0 week, 12 weeks, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Body Surface Area (BSA)</measure>
    <time_frame>At 0 week, 12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>At 0 week, 12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients under the treatment of 50 mg Etanercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients under the treatment of traditional DMARDs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has plaque psoriasis and has shown an unsatisfactory response to traditional DMARDs

          -  18 to 75 years old

          -  has PGA of 3 or more at Day 0

          -  has BSA of 3% or more at Day 0

          -  has psoriasis severe enough to be eligible to systemic therapy

          -  willing to use an effective method of contraception for at least 30 days before Day 0
             and until at least 1 month after the last drug administration;

          -  capable of giving informed consent

          -  with normal or non clinically significant chest X-ray within 6 months prior to Day 0

          -  with negative Purified Protein Derivative (PPD) or Quantiferon TB Gold test within 90
             days prior to Day 0

          -  female patients of childbearing potential have a negative serum pregnancy test

          -  patient is able to start etanercept per the approved product monograph

        Exclusion Criteria:

          -  has used topical steroids, topical tar preparations, or other anti-psoriatic
             preparations within the two weeks prior to Day 0 or during the study period

          -  has presence of erythrodermic, pustular or guttate psoriasis

          -  has had significant infections within the 30 days prior to Day 0

          -  has received investigational drugs within the four weeks prior to screening or during
             the study period

          -  has been treated with systemic anti-psoriatic drugs such as steroids, retinoids,
             cyclosporine, PUVA therapy or methotrexate within the four weeks prior to Day 0 or
             during the study period

          -  received systemic antibiotics within the four weeks prior to Day 0

          -  has been treated with ultraviolet light therapy (UVB, nbUVB) within the two weeks
             prior to Day 0 or during the study period

          -  has used infliximab within 14 days of Day 0 or during the study period

          -  has used other biologic agents for the treatment of psoriasis besides etanercept 8
             weeks prior to Day 0 or during the study period

          -  has had an allergic reaction to infliximab

          -  has an unstable or serious medical condition as defined by the investigator or
             presence of any significant medical condition that might cause this study to be
             detrimental to the patient

          -  uncontrolled or severe comorbidities such as poorly controlled diabetes mellitus, NYHA
             class III or IV heart failure, history of myocardial infarction or cerebrovascular
             accident or transient ischemic attack within three months of screening visit; unstable
             angina pectoris

          -  uncontrolled hypertension, oxygen-dependent severe pulmonary disease

          -  has a known sero-positivity for HIV virus or history of any other immunosuppressive
             disease

          -  has active or chronic Hepatitis B or C

          -  has any mycobacterial disease, patient with a chest X-Ray suggestive of tuberculosis
             or patient taking anti-tuberculosis medication

          -  has a known hypersensitivity to etanercept or one of its components

          -  has received a live attenuated vaccine within the 12 weeks prior to Day 0 or plans to
             receive one during the study

          -  current pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Chengdu Military Area Command PLA</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2014</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chengdu PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yang Min</investigator_full_name>
    <investigator_title>Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

